



THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

# Robust comparison of protein levels across tissues and throughout development using standardized quantitative western blotting

### Citation for published version:

Huang, Y, van der Hoorn, D, Ledahawsky, L, Motyl, A, Jordan, C, Gillingwater, T & Groen, E 2019, 'Robust comparison of protein levels across tissues and throughout development using standardized quantitative western blotting', *Journal of Visualized Experiments (JoVE)*. <https://doi.org/10.3791/59438>

### Digital Object Identifier (DOI):

[10.3791/59438](https://doi.org/10.3791/59438)

### Link:

[Link to publication record in Edinburgh Research Explorer](#)

### Document Version:

Peer reviewed version

### Published In:

*Journal of Visualized Experiments (JoVE)*

### General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

### Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



1 **TITLE:**

2 Robust comparison of protein levels across tissues and throughout development using  
3 standardized quantitative western blotting  
4

5 **AUTHORS AND AFFILIATIONS:**

6 Yu-Ting Huang<sup>1,2</sup>, Dinja van der Hoorn<sup>1,2,\*</sup>, Leire M Ledahawsky<sup>1,2,\*</sup>, Anna M Motyl<sup>1,2,\*</sup>, Crispin Y  
7 Jordan<sup>1</sup>, Thomas H Gillingwater<sup>1,2</sup>, Ewout JN Groen<sup>1,2</sup>  
8

9 <sup>1</sup>Centre for Discovery Brain Sciences, <sup>2</sup>Euan MacDonald Centre for Motor Neurone Disease  
10 Research, The University of Edinburgh, Edinburgh, UK  
11

12 \*These authors contributed equally.  
13

14 *Corresponding Author:*

15 Ewout JN Groen

16 e.groen@ed.ac.uk

17 Tel: (+44)(0)1316 511512  
18

19 *Email Addresses of co-authors:*

20 Yu-Ting Huang (yhuang2@ed.ac.uk)

21 Dinja van der Hoorn (d.vanderhoorn@ed.ac.uk)

22 Leire Ledahawsky (leire.ledahawsky@ed.ac.uk)

23 Anna Motyl (anna.motyl@ed.ac.uk)

24 Crispin Jordan (crispin.jordan@ed.ac.uk)

25 Thomas Gillingwater (t.gillingwater@ed.ac.uk)  
26

27 **KEYWORDS:**

28 Western blotting; Protein analysis; Fluorescence; Development; Whole tissue analysis;  
29 Quantitative biology; Loading control  
30

31 **SUMMARY:**

32 This method describes a robust and reproducible approach for the comparison of protein levels  
33 in different tissues and at different developmental timepoints using a standardized quantitative  
34 western blotting approach.

35 **ABSTRACT:**

36 Western blotting is a technique that is commonly used to detect and quantify protein  
37 expression. Over the years, this technique has led to many advances in both basic and clinical  
38 research. However, as with many similar experimental techniques, the outcome of western blot  
39 analyses is easily influenced by choices made in the design and execution of the experiment.  
40 Specific housekeeping proteins have traditionally been used to normalize protein levels for  
41 quantification, however, these have a number of limitations and have therefore been  
42 increasingly criticized over the past few years. Here, we describe a detailed protocol that we  
43 have developed to allow us to undertake complex comparisons of protein expression variation  
44 across different tissues, mouse models (including disease models), and developmental  
45 timepoints. By using a fluorescent total protein stain and introducing the use of an internal  
46 loading standard it is possible to overcome existing limitations in the number of samples that  
47 can be compared within experiments and systematically compare protein levels across a range  
48 of experimental conditions. This approach expands the use of traditional western blot  
49 techniques, thereby allowing researchers to better explore protein expression across different  
50 tissues and samples.

51

52 **INTRODUCTION:**

53 Western blotting is a technique that is commonly used to detect and quantify protein  
54 expression, including in tissue homogenates or extracts. Over the years, this technique has led  
55 to many advances in both basic and clinical research, where it can be used as a diagnostic tool  
56 to identify the presence of disease<sup>1,2</sup>. Western blotting was first described in 1979 as a method  
57 to transfer proteins from polyacrylamide gels to nitrocellulose sheets and subsequently  
58 visualize proteins using secondary antibodies that were either radioactively labelled or  
59 conjugated to fluorescein or peroxidase<sup>3</sup>. Through the development of commercially available  
60 kits and equipment, western blotting methods have been increasingly standardized and  
61 simplified over the years. Indeed, the technique is now readily performed by scientists with  
62 varying backgrounds and levels of experience. However, as with many similar experimental  
63 techniques, the outcome of western blot analyses is easily influenced by choices made in the  
64 design and execution of the experiment. It is important, therefore, that the accessibility of  
65 standardized western blotting methods does not obscure the need for careful experimental  
66 planning and design. Experimental considerations include, but are not limited to, sample  
67 preparation and handling, selection and validation of antibodies for protein detection, and gel-  
68 to-membrane transfer efficiency of particularly small or large (<10 or >140 kDa) proteins<sup>4-9</sup>.  
69 Protein quality of the original sample plays a significant role in determining the outcome of the  
70 subsequent western blot analysis. As protein can be extracted from a wide variety of samples  
71 and sources, including cell lines, tissues from animal models, and post-mortem human tissues,  
72 consistency in handling and processing is required to obtain reproducible results. For example,

73 when long-term storage of samples for protein extraction is required, it is important to realize  
74 that, although protein is generally stable at -80°C, differences in protein stability between  
75 extracted proteins and intact tissues at -80°C have been reported<sup>10</sup>. Moreover, to obtain  
76 reproducible estimates of protein quantities, consistent homogenization of samples is crucial.  
77 Optimizing different lysis buffers and homogenization methods (e.g. manual homogenization  
78 compared to automated methods) may be required before starting a large-scale quantitative  
79 experiment.

80 Normalization strategies to correct for protein loading and quantification variability are  
81 essential to obtain robust, quantitative results of protein expression. Housekeeping proteins  
82 such as  $\beta$ -actin,  $\alpha$ -tubulin,  $\beta$ -tubulin, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)  
83 have traditionally been used to normalize protein levels for quantification. However,  
84 normalization to specific housekeeping proteins for quantification purposes has been  
85 increasingly criticized over the past few years<sup>11,12</sup>. For example, the expression of housekeeping  
86 proteins can change across different developmental stages<sup>13,14</sup>, across tissues from the same  
87 animal<sup>4</sup>, and under various disease conditions<sup>4,15-17</sup>. Therefore, the use of specific housekeeping  
88 proteins limits the possibilities of making more complex comparisons between protein  
89 expression from different tissues, at different timepoints and under varying experimental  
90 conditions. An alternative to housekeeping proteins to control for protein loading variation is  
91 the use of a total protein stain (TPS) that labels and visualizes all proteins present in a sample.  
92 TPS allows signal normalization based on total protein load rather than levels of one specific  
93 protein and therefore quantification of TPS signal should be comparable and reproducible  
94 regardless of experimental condition, sample type or developmental timepoint. Examples of  
95 total protein stains include Ponceau S, stain-free gels, Coomassie R-350, Sypro-Ruby,  
96 Epicocconone, Amydo Black, and Cy5 (reviewed in ref. 18). Each of these methods has specific  
97 advantages and limitations and method selection depends on the time and tools available as  
98 well as the experimental setup<sup>4,18</sup>.

99 In addition to using a TPS to correct for within-membrane loading and quantification  
100 variability, it may be necessary to compare samples between different membranes, particularly  
101 when performing large-scale protein expression analysis. However, variability in factors such as  
102 antibody binding efficiency and total protein stain intensity may introduce further variability  
103 between protein samples that are analyzed on separate gels and membranes. For robust  
104 quantification in this situation it is therefore necessary to introduce a further normalization  
105 step to account for between-membrane variability. This can be achieved by including an  
106 internal loading standard on each of the separately analyzed membranes that is kept constant  
107 across experiments. This standard can take the form of any protein lysate that can be obtained  
108 in sufficient quantities to be used across all membranes included in the experiment. Here we  
109 use a lysate of mouse brain (obtained from 5 day old control mice), as brain is readily  
110 homogenized and the obtained protein lysate contains a significant amount of protein at a high

111 concentration. Loading an internal standard in triplicate allows samples on separate  
112 membranes to be normalized and compared directly.

113 Here, we describe a detailed protocol that we have developed to allow us to undertake  
114 complex comparisons of protein expression variation across different tissues, mouse models  
115 (including disease models), and developmental timepoints<sup>19</sup>. By combining a fluorescent TPS  
116 with the use of an internal loading standard we were able to overcome existing limitations in  
117 the number of samples and experimental conditions that can be compared within a single  
118 experiment. This approach expands the use of traditional western blot techniques, thereby  
119 allowing researchers to better explore protein expression across different tissues and samples.

120

#### 121 **PROTOCOL:**

122 This protocol has been optimized using standardized, commercially available kits and reagents  
123 in order to increase reproducibility (see **Table of Materials**).

124

#### 125 **Ethics Statement:**

126 Tissues for this procedure were obtained from animal studies that were approved by the  
127 internal ethics committee at the University of Edinburgh and were performed in concordance  
128 with institutional and UK Home Office regulations under the authority of relevant personal and  
129 project licenses.

130

### 131 **1. Preparation of samples**

#### 132 **1.1. Protein extraction**

133 1.1.1. Transfer snap-frozen cell or tissue samples from -80°C on dry ice,  
134 thaw on ice, and wash as required with ice cold 1xPBS (for details on tissues  
135 and PBS washes, see **Table 1**). Avoid unnecessary freeze-thaw cycles as this  
136 will affect protein quality.

137 1.1.2. Add radioimmunoprecipitation assay (RIPA) buffer (25 mM Tris-HCl  
138 (pH 7.6), 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS)  
139 containing 1x protease inhibitor to each sample, using the optimal amount  
140 per tissue weight (see **Table 1** for recommendations).

141 *NOTE:* Depending on the application, the type and amount of  
142 homogenization buffer may need further optimization.

143 1.1.3. Use a hand-held electric homogenizer with a polypropylene pestle to  
144 homogenize tissue samples. Between each sample wash the pestle in double-  
145 distilled water and dry with a clean tissue. Change the pestle between  
146 different experimental conditions and tissues.

147 1.1.4. Leave the samples on ice for 10 minutes after homogenization.  
148 Centrifuge the samples at >10,000 x *g* at 4°C for 10 minutes.

149 1.1.5. Transfer the supernatant to a new tube on ice without disturbing the  
150 pellet. The supernatant is the protein sample. Store the extracted protein at -  
151 80°C or directly proceed to measuring the protein concentration.

## 152 1.2. **Quantification and normalization of protein concentration**

153 1.2.1. Measure the protein concentration using a bicinchoninic acid (BCA)  
154 assay. Prepare a BCA assay mix according to the manufacturer's instructions  
155 in a 96-well optical plate using 200 µL of BCA mix per well.

156 *NOTE:* Other quantification methods such as Lowry and Bradford assays can  
157 also be used to determine protein concentration as long as protein  
158 concentration is quantified consistently across experiments.

159 1.2.2. Prepare bovine serum albumin (BSA) standards at increasing  
160 concentrations in triplicate and add 1 µL of each protein sample in duplicate.  
161 Incubate the 96-well plate in a preheated heat block at 60°C for 10 minutes  
162 or longer if the protein concentration is expected to be low.

163 1.2.3. After incubation, measure the absorption at 560 nm using a plate  
164 reader.

165 1.2.4. Export the plate reader measurements and calculate the protein  
166 concentration by comparing the average absorbance values of each sample  
167 to a standard curve obtained using the protein standard. The R-squared  
168 value for the standard curve should be greater than or equal to 0.98 to  
169 accurately estimate sample protein concentration.

170 1.2.5. Normalize the amount of protein by preparing dilutions of protein  
171 samples in sample buffer and ultrapure water. The total volume can be  
172 adjusted depending on the type of gel used. Loading 30 µg of protein per  
173 lane as a starting amount is recommended. Add reducing agent such as  
174 dithiothreitol (DTT; final concentration 5 mM) or beta-mercaptoethanol (final  
175 concentration 200 mM) to each sample as required. Pipette undiluted beta-  
176 mercaptoethanol in a fume hood.

177 1.2.6. Incubate the samples in a heat block at 70°C for 10 minutes. Put the  
178 samples on ice, vortex and spin down briefly to collect. Keep on ice until  
179 loading the gel.

180

## 181 2. **Gel electrophoresis of protein samples**

### 182 2.1. **Device and gel set up**

183 2.1.1. Setup a precast 4–12% Bis-Tris gradient gel (see **Table of Materials**)  
184 in the gel electrophoresis chamber system. Rinse gels using double-distilled  
185 water before use.

186 *NOTE:* Depending on the size, interactions and abundance of the protein

187 of interest, gels with a different gradient, buffering agent or well size and  
188 number can be used.

189 2.1.2. Add 500 mL of 1x MES SDS running buffer diluted in double-distilled  
190 water per tank. Carefully remove the comb from the gels after adding the  
191 running buffer without disturbing the wells in the stacking gel.

## 192 2.2. **Protein loading**

193 2.2.1. Load 3.5  $\mu$ L of a protein standard into the well. Depending on the  
194 sample layout, loading a protein ladder on both sides of the gel can aid in  
195 more accurately estimating protein size. Use fine-tipped gel loading tips for  
196 more accurate sample loading.

197 2.2.2. When using an internal standard for between-membrane  
198 normalization (see step 5 below and Discussion), load an amount that is  
199 equal to the other samples into the first 3 wells next to the protein ladder.

200 2.2.3. Load 30  $\mu$ g of each sample in the remaining wells. Add 1x sample  
201 buffer to all empty wells.

## 202 2.3. **Electrophoresis**

203 2.3.1. Assemble the gel tank after loading the samples. Run the samples  
204 through the stacking gel at 80V for 10 minutes followed by 150 V for an  
205 additional 45-60 mins.

206

## 207 3. **Protein transfer**

208 Protein transfer in this protocol is performed using a commercially available semi-dry blotting  
209 system (see **Table of Materials**) for fast and consistent outcomes.

210 3.1. Prepare protein transfer by pre-soaking filter paper in double-distilled water  
211 and making sure the gel knife, plastic Pasteur pipette, blotting roller and forceps are  
212 ready to use.

213 3.2. Open the transfer stack by carefully removing all wrapping foil. Remove the top  
214 from the bottom stack and set it aside. Quickly moisten the membrane on the  
215 bottom stack with several drops of electrophoresis running buffer (2-3 mL). Once  
216 the transfer stack is open, it is important to prevent the PVDF membrane from  
217 drying out.

218 3.3. After stopping the electrophoresis, open the pre-cast gel using the gel knife and  
219 cut off the stacking gel. Cut the gel around its edges to free it from the plastic cast.  
220 Keep the gel knife wet to prevent damage to the gel.

221 3.4. Assemble the transfer stack from bottom to top: bottom stack (containing the  
222 PVDF membrane), protein gel, filter paper. Use the blotting roller to remove all air  
223 bubbles. Place the top stack on top of the filter paper and roll the stack again to  
224 remove air bubbles. Do not push too strongly as this may cause the gel to deform

225 during protein transfer.  
226 3.5. Transfer the whole stack into the transfer device with the electrode on the left  
227 side of the device and place the gel sponge on top of the stack so that it is aligned  
228 with the corresponding electrical contacts on the device. Close the lid, select and  
229 start the appropriate program (20V for 7 minutes is a recommended starting point).  
230 3.6. When finished, leave the lid closed for two minutes to allow the stack to cool  
231 down and to prevent the membrane from drying out. Remove the transfer stack and  
232 cut the membrane to the gel size. Wash the cut membrane quickly with double-  
233 distilled water before continuing with the total protein stain.  
234

#### 235 4. Total protein staining

236 Using fluorescent detection provides a substantial benefit over more traditional approaches  
237 (e.g. ECL detection), as the linear range and sensitivity can be much better controlled<sup>4</sup>.  
238 Therefore, in steps 4 and 5 a fluorescent TPS and fluorescent secondary antibodies are used  
239 (see **Table of Materials**).

240 4.1. Roll the membrane into a 50-mL tube with the protein side facing inwards.  
241 Because of light sensitivity of the fluorescent TPS and secondary antibodies, all  
242 subsequent steps are carried out in the dark.  
243 4.2. Add 5mL of protein stain solution (see **Table of Materials**) and incubate on a  
244 roller for 5 minutes at room temperature. Because TPS and wash buffer contain  
245 methanol carry these steps out in a fume hood.  
246 4.3. Discard the staining solution and wash twice quickly with the 5mL wash solution  
247 (6.3% acetic acid in 30% methanol). Place the tube briefly back on the roller between  
248 wash steps. Rinse the membrane briefly with MilliQ water before continuing.  
249

#### 250 5. Blocking, antibody incubation and detection

251 5.1. **Blocking the membrane**  
252 Add 3 mL of blocking buffer (see **Table of Materials**) to the 50 mL tube  
253 containing the membrane. Incubate the membrane on a roller for 30 minutes at  
254 room temperature. Depending on the choice of antibody, the type of blocking  
255 buffer used may require optimization.

#### 256 5.2. Primary antibody incubation

257 5.2.1. Discard the blocking buffer and replace with the primary antibody at  
258 the appropriate, optimized concentration (**Figure 1** and **Figure 2**: mouse-anti-  
259 SMN, at 1:1000, diluted in blocking buffer).

260 *NOTE:* Adequate optimization of primary antibodies should include  
261 confirmation that the antibody detects a protein product of the right size  
262 whilst showing no or minimal binding to other, unspecific protein products. If



263 possible, test and compare multiple antibodies against the protein of interest.  
264 5.2.2. Incubate the membrane on a roller overnight at 4°C. The next day,  
265 remove the antibody solution and wash 6 times 5 minutes with 1x PBS on a  
266 roller at room temperature (RT).

267 5.3. **Secondary antibody incubation**

268 5.3.1. Prepare the specific secondary antibody at 1:5,000 against the host of  
269 the primary antibody in 5 mL blocking buffer. Other secondary antibodies  
270 may require other dilutions or the use of alternative blocking buffers.

271 5.3.2. Incubate the membrane with the secondary antibody solution on a  
272 roller for one hour at RT. After incubation, wash the membrane three times  
273 30 minutes with 1x PBS on a roller.

274 5.3.3. Dry the membrane and keep the membrane protected from light  
275 using aluminum foil until detection. Membranes can be kept at 4°C for long  
276 term storage.

277 5.4. **Image acquisition**

278 5.4.1. Login to the computer attached to the scanner. Place the membrane  
279 on the scanner with the protein side facing down and select the scanning  
280 area in the software.

281 5.4.2. Optimize the laser intensity for both (700nm and 800nm) channels,  
282 by confirming no saturation occurs. Acquire the images in both channels and  
283 export the images for further analysis (see below).

284

285 **6. Western blot analysis and quantification**

286 These recommendations are based on the freely available Image Studio software. However,  
287 comparable analyses can also be done using other software packages, such as ImageJ.

288 6.1. **Import the file**

289 Create a local workspace on the computer used for analysis. This generates a  
290 database of image files for acquired western blots. Import files obtained on the  
291 scanner and select the image for analysis.

292 6.2. **TPS analysis**

293 6.2.1. Display the 700nm channel to show the total protein staining result.  
294 An example of a TPS image is included in **Figure 1** in which different tissues  
295 from neonatal (P5) (**Figure 1A-B**) and 10-week old mice (**Figure 1C-D**) are  
296 compared directly. Similarly, **Figure 2** shows an example of a direct  
297 comparison of brain tissue from mice of different ages.

298 6.2.2. Select “Analysis” tab from top right corner and select “Add  
299 Rectangle” to define the area of interest for normalization (as illustrated in  
300 **Figure 1B** and **1D**). Copy and paste the first rectangle area onto each

301 individual sample to ensure the defined region is at the same size for all  
302 analyzed lanes.  
303 6.2.3. Copy the result from the “Shapes” tab in the bottom left corner of  
304 the software.

### 305 6.3. Quantification

306 The optimal approach for quantifying samples depends on the experimental  
307 design. We will here provide an illustrative example of the detection of the  
308 survival motor neuron protein (Smn; a key protein involved in the  
309 neuromuscular disease spinal muscular atrophy<sup>20,21</sup>), that is known to decrease  
310 over time<sup>19</sup> and how normalization of Smn signal intensity to TPS provides  
311 reliable estimates of protein expression development.

312 6.3.1. **Figure 2** shows a decrease of Smn expression with increasing age of  
313 the animal with TPS as protein loading control. Repeat Step 6.2.1-6.2.3 to  
314 quantify protein loading (**Figure 2B**). Repeat Step 6.2.1-6.2.3 in the 800nm  
315 channel (**Figure 2A**) to analyze the protein of interest.

316 6.3.2. Copy the results from both TPS and protein of interest to a  
317 spreadsheet program. On the spreadsheet, first normalize the protein  
318 loading by determining the highest TPS signal and dividing each TPS  
319 signal value by this value to obtain the normalized protein loading value.

320 6.3.3. Divide the 800nm signal value from each individual sample by its  
321 corresponding normalized protein value to calculate the relative protein  
322 expression ratio in different samples.

323 6.3.4. After the first normalization, various time points or tissues can be  
324 compared to the average value of the internal standard to allow direct  
325 comparisons across different membranes and experiments.

326

## 327 7. Statistics

328 To determine any statistically significant differences in protein expression across complex and  
329 large groups of samples, appropriate statistical methodology is required. Although a detailed  
330 discussion of statistical background goes beyond the scope of this paper, we want to highlight  
331 several considerations and detail a successful approach that we have used previously<sup>19</sup>.

332 As for many experiments, protein quantification measurements do not represent  
333 completely independent data. Here, for example, multiple tissues are generally obtained from  
334 single animals to determine protein levels across multiple organs at a single experimental time-  
335 point. Therefore, we used a mixed effects models to analyze differences in protein expression  
336 over time, and between tissues. In general, mixed effects models provide an effective means to  
337 deal with non-independence and thereby avoid pseudo-replication<sup>22,23</sup>. In the present case,  
338 mixed effects models increase statistical power by accounting for repeated measurements

339 among tissues, within individuals. We use the statistical software package R to perform these  
340 analyses, as this is freely available and versatile. However, other commercially available  
341 packages may be able to perform similar analyses.

342 The current experimental design involves a “split plot” design because each mouse  
343 belonged to only one age group. Therefore, we modeled individual mice (mouse ID) as a  
344 random effect with a unique identifier; we also accounted for tissue, age, and their interaction  
345 as fixed effects. We modeled the data using the function lmer in the R library, lme4. As a quality  
346 control step, we visualized residuals to assess the assumptions of equal variance and a normal  
347 distribution and transformed the data where necessary to meet these assumptions. To test for  
348 a significant interaction between tissue and age, we fit an identical model that lacked this  
349 interaction, and compared the models using parametric bootstrapping (R function PBmodcomp  
350 in the library, pbkrtest). Where significant interactions arose, we used the function emmeans  
351 (in the emmeans R library) to determine the cause of the interaction. For example, we  
352 compared mean expression among age classes within each tissue; a significant interaction may  
353 arise between age and tissue if, say, two given age classes differed significantly for one tissue  
354 but not another. In summary, these approaches provide a way to extend the robustness of  
355 conclusions from western blot experiments by providing statistical support to these results.

356

#### 357 **REPRESENTATIVE RESULTS:**

358 We include examples of the use of TPS and an internal standard to facilitate comparisons of  
359 protein levels across tissues and time points. **Figure 1** shows results from western blotting on  
360 protein extracted from tissues obtained from neonatal (postnatal day 5) in comparison to adult  
361 mice (10-week old). TPS and Smn immunoblot are shown in **Figure 1A** and **1C**. Quantification of  
362 fluorescence intensity of the TPS was achieved by measuring the fluorescence intensity inside  
363 the rectangle box on each lane and its results are shown in the tables in **Figure 1B** and **1D**. Note  
364 that samples from different tissues are characterized by different TPS protein band patterns  
365 and therefore it is necessary to use the whole lane for normalization purposes. Indeed, when  
366 whole lanes are analysed, the fluorescence intensity remains relatively similar across samples,  
367 indicating TPS for normalization is suitable for this purpose. An internal standard consisting of a  
368 P5 brain lysate mixture was also included to illustrate how it can be used for further  
369 comparisons between different membranes. Furthermore, in **Figure 2** we show how a  
370 fluorescent TPS can be used to compare protein levels at different developmental time points.  
371 Here, we show Smn levels in brain lysates from neonatal (P5), weaning age (P20) and adult  
372 (10W) mice (**Figure 2A**). Although Smn levels clearly decrease with age, TPS quantification  
373 remains constant as illustrated in **Figure 2B**.

374

#### 375 **FIGURE AND TABLE LEGENDS:**

376 **Figure 1.** Western blots showing TPS and Smn protein levels in mouse tissues at two different

377 ages. (A,C) TPS and Smn protein for P5 (A) and 10 week-old (C) mice. (B,D) The fluorescence  
378 intensity of whole-lane TPS was calculated and is indicated (in arbitrary units). M: marker /  
379 protein standard; kDa: kilodalton; a.u.: arbitrary unit; P5: postnatal day 5; 10W: 10 weeks.

380 **Figure 2.** Analysis of Smn expression in mouse tissues at different developmental time points.  
381 (A) Brain lysates from tissue obtained from P5, P20 and 10 week-old mice was analyzed using  
382 TPS (top panel) and SMN (bottom panel). (B) The fluorescence intensity of the TPS was  
383 calculated and is indicated in arbitrary units. M: marker / protein standard; kDa: kilodalton;  
384 a.u.: arbitrary unit; P5: postnatal day 5; P20: postnatal day 20; 10W: 10 weeks.

385 **Table 1.** Overview of expected tissues weights and corresponding recommendations for PBS  
386 washes and lysis buffer volume to be used for homogenization. The weights are indications for  
387 tissue obtained from postnatal day 8 (P8) mice. PBS and lysis buffer volumes can be scaled up  
388 and down according to experimental needs.

389 **Table of Materials.** Overview of suggested commercially available reagents, equipment,  
390 consumable and software used for the western blot analyses described in this protocol.

391

## 392 **DISCUSSION:**

393 With the appropriate experimental design, control measures and statistical analysis, western  
394 blotting can be used to make reliable quantitative estimates of protein expression within and  
395 between a varied range of biological samples. The protocol we describe in the current  
396 manuscript aims to serve as a guideline for researchers looking to use western blotting to  
397 undertake quantitative analysis across larger and more complex groups of samples, by using a  
398 combination of fluorescence-based detection methods, total protein loading normalization and  
399 internal standards. Although the focus here is on determining and comparing protein  
400 expression from different mouse tissues and at different ages, this approach can also be  
401 extended to compare protein expression in other experimental conditions.

402 A central step in our current protocol is the normalization of proteins of interest to total  
403 protein loaded by quantifying a fluorescent total protein stain. TPS normalization corrects for  
404 variation in sample loading and error margins in protein quantification methods. However,  
405 because the number of protein samples that can be analyzed on a single membrane is often  
406 limited, further normalization may be required to compare multiple membranes. Indeed,  
407 variability between how proteins are detected on different membranes (due to for example  
408 antibody incubation time or temperature variation) may cause variation beyond that  
409 introduced through loading and quantification steps of the protocol. Here, we use an internal  
410 standard that consists of a single protein lysate mix that is loaded in triplicate on each gel and  
411 allows for comparison and normalization between gels/membranes. Theoretically this could be  
412 any protein sample, as long as it can be made in sufficient quantities so that the same sample  
413 can be used for all experiments. In our experiments we use a mixture of brain protein lysates,  
414 as brain homogenates contain large quantities of protein and are typically obtained at a high

415 concentration. Averaging quantification of triplicate standard should further increase the  
416 accuracy of quantifications across membranes and contribute to the reproducibility of the  
417 experiment.

418 Protein levels can be determined by a number of different techniques and the preferred  
419 method depends on the sample type being analyzed and the goal of the experiment.  
420 Reproducible quantification of western blot works best in situations where experimental  
421 conditions can be well-controlled, such as when using mouse or other animal models of a  
422 defined genetic background. In contrast, in many experiments using human patient samples  
423 this may be less feasible as age, genetic variability and tissue sampling times are much harder  
424 to control than in (animal) model systems. Plate-based techniques such as ELISA might be more  
425 suitable for these analyses, although the careful validation of antibody specificity is crucial. For  
426 example, in fragile X syndrome research, antibodies have been shown to detect different  
427 isoforms and when used in ELISA this would lead to overestimation of the total amount of  
428 protein as ELISA determines a signal for all isoforms combined<sup>24</sup>. Optimal choices for methods  
429 to determine protein expression are therefore depending on context, sample type and the  
430 research question that is being investigated.

431 Performing adequate statistical analysis is a prerequisite for the reliability of any  
432 conclusions drawn from the quantification of biological data. Statistically analyzing complex  
433 data as generated by comparing different tissues, time points or other experimental conditions  
434 and combinations thereof may require more advanced statistical modelling than ANOVA with  
435 post-hoc testing can deliver. For more complex statistical modelling, such as the mixed-effects  
436 model approach we describe in the current manuscript, it may be advisable to seek further  
437 advice from biostatisticians. Adequate statistical analysis of large-scale protein expression can  
438 greatly improve the robustness of the outcomes and the reliability and reproducibility of  
439 results.

440 In summary, the experimental approach we describe here provides a robust and  
441 reproducible method for researchers that want to determine protein expression using western  
442 blot in complex samples allowing to answer new and exciting research questions.

443  
444 **ACKNOWLEDGMENTS:**

445 E.J.N.G. is supported by the Wellcome Trust (grant 106098/Z/14/Z). Other funding has been  
446 provided by the SMA Trust (SMA UK Consortium; T.H.G. & Y-T.H.), SMA Europe (T.H.G, D.v.D.H.  
447 & E.J.N.G.), the University of Edinburgh DTP in Precision Medicine (T.H.G., L.L. & A.M.M.), and  
448 the Euan MacDonald Centre for Motor Neurone Disease Research (T.H.G).

449  
450 **DISCLOSURES:**

451 The authors have no competing interests to disclose.

452

453 **REFERENCES:**

- 454 1 Bertonni, T. A., Perenha-Viana, M. C., Patussi, E. V., Cardoso, R. F. & Svidzinski, T. I.  
455 Western blotting is an efficient tool for differential diagnosis of paracoccidioidomycosis  
456 and pulmonary tuberculosis. *Clinical and Vaccine Immunology*. **19** (11), 1887-1888,  
457 doi:10.1128/CVI.00252-12, (2012).
- 458 2 Hutchinson, A. B. *et al.* Costs and outcomes of laboratory diagnostic algorithms for the  
459 detection of HIV. *Journal of Clinical Virology*. **58 Suppl 1** e2-7,  
460 doi:10.1016/j.jcv.2013.10.005, (2013).
- 461 3 Towbin, H., Staehelin, T. & Gordon, J. Electrophoretic transfer of proteins from  
462 polyacrylamide gels to nitrocellulose sheets: procedure and some applications.  
463 *Proceedings of the National Academy of Sciences of the United States of America*. **76** (9),  
464 4350-4354 (1979).
- 465 4 Eaton, S. L. *et al.* Total protein analysis as a reliable loading control for quantitative  
466 fluorescent Western blotting. *PLoS One*. **8** (8), e72457,  
467 doi:10.1371/journal.pone.0072457, (2013).
- 468 5 Ghosh, R., Gilda, J. E. & Gomes, A. V. The necessity of and strategies for improving  
469 confidence in the accuracy of western blots. *Expert Rev Proteomics*. **11** (5), 549-560,  
470 doi:10.1586/14789450.2014.939635, (2014).
- 471 6 Jensen, B. C., Swigart, P. M. & Simpson, P. C. Ten commercial antibodies for alpha-1-  
472 adrenergic receptor subtypes are nonspecific. *Naunyn-Schmiedeberg's Archives of*  
473 *Pharmacology*. **379** (4), 409-412, doi:10.1007/s00210-008-0368-6, (2009).
- 474 7 Jositsch, G. *et al.* Suitability of muscarinic acetylcholine receptor antibodies for  
475 immunohistochemistry evaluated on tissue sections of receptor gene-deficient mice.  
476 *Naunyn-Schmiedeberg's Archives of Pharmacology*. **379** (4), 389-395,  
477 doi:10.1007/s00210-008-0365-9, (2009).
- 478 8 Smejkal, G. & Gallagher, S. Determination of semidry protein transfer efficiency with  
479 transverse gradient gel electrophoresis. *Biotechniques*. **16** (2), 196-198, 200-192 (1994).
- 480 9 Eaton, S. L. *et al.* A guide to modern quantitative fluorescent western blotting with  
481 troubleshooting strategies. *Journal of Visualized Experiments*. (93), e52099,  
482 doi:10.3791/52099, (2014).
- 483 10 Hunter, G., Roche, S. L., Somers, E., Fuller, H. R. & Gillingwater, T. H. The influence of  
484 storage parameters on measurement of survival motor neuron (SMN) protein levels:  
485 implications for pre-clinical studies and clinical trials for spinal muscular atrophy.  
486 *Neuromuscular Disorders*. **24** (11), 973-977, doi:10.1016/j.nmd.2014.05.013, (2014).
- 487 11 Fosang, A. J. & Colbran, R. J. Transparency Is the Key to Quality. *Journal of Biological*  
488 *Chemistry*. **290** (50), 29692-29694, doi:10.1074/jbc.E115.000002, (2015).
- 489 12 Taylor, S. C., Berkelman, T., Yadav, G. & Hammond, M. A defined methodology for  
490 reliable quantification of Western blot data. *Molecular Biotechnology*. **55** (3), 217-226,  
491 doi:10.1007/s12033-013-9672-6, (2013).
- 492 13 Goasdoue, K., Awabdy, D., Bjorkman, S. T. & Miller, S. Standard loading controls are not  
493 reliable for Western blot quantification across brain development or in pathological  
494 conditions. *Electrophoresis*. **37** (4), 630-634, doi:10.1002/elps.201500385, (2016).
- 495 14 Rocha-Martins, M., Njaine, B. & Silveira, M. S. Avoiding pitfalls of internal controls:  
496 validation of reference genes for analysis by qRT-PCR and Western blot throughout rat

497 retinal development. *PLoS One*. **7** (8), e43028, doi:10.1371/journal.pone.0043028,  
498 (2012).

499 15 Aghamaleky Sarvestany, A. *et al.* Label-free quantitative proteomic profiling identifies  
500 disruption of ubiquitin homeostasis as a key driver of Schwann cell defects in spinal  
501 muscular atrophy. *Journal of Proteome Research*. **13** (11), 4546-4557,  
502 doi:10.1021/pr500492j, (2014).

503 16 Fuller, H. R. *et al.* Spinal Muscular Atrophy Patient iPSC-Derived Motor Neurons Have  
504 Reduced Expression of Proteins Important in Neuronal Development. *Frontiers in*  
505 *Cellular Neuroscience*. **9** 506, doi:10.3389/fncel.2015.00506, (2015).

506 17 Liu, N. K. & Xu, X. M. beta-tubulin is a more suitable internal control than beta-actin in  
507 western blot analysis of spinal cord tissues after traumatic injury. *Journal of*  
508 *Neurotrauma*. **23** (12), 1794-1801, doi:10.1089/neu.2006.23.1794, (2006).

509 18 Moritz, C. P. Tubulin or Not Tubulin: Heading Toward Total Protein Staining as Loading  
510 Control in Western Blots. *Proteomics*. **17** (20), doi:10.1002/pmic.201600189, (2017).

511 19 Groen, E. J. N. *et al.* Temporal and tissue-specific variability of SMN protein levels in  
512 mouse models of spinal muscular atrophy. *Human Molecular Genetics*. **27** (16), 2851-  
513 2862, doi:10.1093/hmg/ddy195, (2018).

514 20 Chaytow, H., Huang, Y. T., Gillingwater, T. H. & Faller, K. M. E. The role of survival motor  
515 neuron protein (SMN) in protein homeostasis. *Cellular and Molecular Life Sciences*.  
516 doi:10.1007/s00018-018-2849-1, (2018).

517 21 Groen, E. J. N., Talbot, K. & Gillingwater, T. H. Advances in therapy for spinal muscular  
518 atrophy: promises and challenges. *Nature Reviews: Neurology*. **14** (4), 214-224,  
519 doi:10.1038/nrneurol.2018.4, (2018).

520 22 Fitzmaurice, G. M., Laird, N. M. & Ware, J. H. *Applied longitudinal analysis*. (Wiley-  
521 Interscience, 2004).


522 23 Jordan, C. Y. Population sampling affects pseudoreplication. *PLoS Biology*. **16** (10),  
523 e2007054, doi:10.1371/journal.pbio.2007054, (2018).

524 24 LaFauci, G., Adayev, T., Kascsak, R. & Brown, W. T. Detection and Quantification of the  
525 Fragile X Mental Retardation Protein 1 (FMRP). *Genes (Basel)*. **7** (12),  
526 doi:10.3390/genes7120121, (2016).

527

**Figure 1.**

**Neonatal (P5)**



**Adult (10W)**







Figure 2.



**Table 1.**

<b>Tissue</b>	<b>Approx. weight*</b>	<b>1xPBS wash (4 °C)</b>	<b>Repeat wash</b>	<b>Homogenizing buffer **</b>
Spinal cord	40 mg	150 µL	3x	100 µL
Muscle (GC)	20 mg	150 µL	3x	100 µL
Brain	240 mg	400 µL	4x	400 µL
Heart	60 mg	400 µL	4x	200 µL
Liver	130 mg	400 µL	4x	400 µL
Kidney	45 mg	400 µL	4x	200 µL

\* These weights are indicative values for tissue obtained from P8 mice.

\*\* These volumes are indications and can be further adjusted according to the weight of the tissue.

**Table of Materials.**

<b>Name of Material/ Equipment</b>	<b>Company</b>	<b>Catalog Number</b>	<b>Comments/Description</b>
Fine Tipped Gel Loading Tips	Alpha Laboratories	GL20057SNTL	
Halt Protease Inhibitor Cocktail, EDTA-free 100x 5mL	ThermoFisher Scientific	78437	
Handheld homogeniser	VWR Collection	431-0100	
iBlot 2 Gel Transfer Device	ThermoFisher Scientific	IB21001	
iBlot Transfer Stack, PVDF, regular size	ThermoFisher Scientific	IB401031	
Image Studio Lite	Licor	N/A	Free download from <a href="https://www.licor.com/bio/products/software/image_studio_lite/">https://www.licor.com/bio/products/software/image_studio_lite/</a>
IRDye 800CW secondary antibodies	Licor	--	Select appropriate secondary antibody that is specific against host of primary antibody.
Micro BCA Protein Assay Kit	ThermoFisher Scientific	23235	
Novex Sharp Pre-stained Protein Standard	ThermoFisher Scientific	LC5800	
NuPAGE 4-12% Bis-Tris Protein Gels, 1.0 mm, 15-well	ThermoFisher Scientific	NP0323BOX	
NuPAGE LDS Sample Buffer (4X)	ThermoFisher Scientific	NP0007	
NuPAGE MOPS SDS Running Buffer (20X)	ThermoFisher Scientific	NP0001	
Odyssey Blocking Buffer	Licor	927-40000	
Purified Mouse anti-SMN (survival motor neuron) monoclonal antibody	BD Transduction Laboratories	610646	Is used extensively in the SMN/SMA literature and gives consistent results regardless of lot number
REVERT Total Protein Stain, 250 mL	Licor	926-11021	
REVERT Wash Solution	Licor	926-11012	
RIPA Lysis and Extraction Buffer	ThermoFisher Scientific	89900	
XCell SureLock Mini-Cell	ThermoFisher Scientific	E10001	